13292.00005/UNMC 63102 US

MAY 0 4 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Intre th	e Application of)	Examiner: F. VanderVegt
Sam D. Sanderson et al.)	Group Art Unit: 1644
Application No. 09/051,685)	Gloup Air Ollit. 1044
Filed: August 19, 1998)	Response to Paper No. 13
For:	Compositions and Methods for Enhancing Immune Responses Mediated by Antigen- Presenting Cells)))	

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 C.F.R. §1.111

In response to the Official Action dated November 8, 2000, and the Notice of Non-compliant Amendment dated April 2, 2001, please amend the above-identified patent application as follows:

In the specification:

On page 8, line 41 through page 9, line 12, please insert the following substitute paragraph:

Antigen-presenting cells contemplated for targeting according to the present invention include, but are not limited to, monocytes, dendritic cells, macrophages, B cells and some T cells. In preferred embodiments of the invention, the characteristic determinant on the selected APC is a cell surface receptor and the targeting moiety of the APC-targeted antigen is a ligand that binds to the receptor. It is particularly preferred that the cell surface receptor be an immunomodulatory receptor. Suitable cell surface receptors include, but are not limited to, C5a receptor, IFNγ receptor, CD21 (C3d receptor), CD64 (FcγRI receptor), and CD23 (Fc∈RII receptor).